<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77195">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01835145</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00821</org_study_id>
    <secondary_id>NCI-2013-00821</secondary_id>
    <secondary_id>CALGB-A091201</secondary_id>
    <secondary_id>A091201</secondary_id>
    <secondary_id>A091201</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>U10CA180821</secondary_id>
    <nct_id>NCT01835145</nct_id>
  </id_info>
  <brief_title>Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye</brief_title>
  <official_title>Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well cabozantinib-s-malate works compared with
      temozolomide or dacarbazine in treating patients with melanoma of the eye.
      Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as temozolomide and dacarbazine,
      work in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the progression-free survival rate at 4 months (PFS4) of patients with ocular
      melanoma treated with cabozantinib (cabozantinib-s-malate) or temozolomide (or dacarbazine).

      SECONDARY OBJECTIVES:

      I. Estimate the distribution of progression-free survival (PFS) times. II. Estimate the
      distribution of overall survival (OS) times. III. Estimate the confirmed response rate as
      determined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

      IV. Assess the safety of these agents by examining the toxicity profile. V. Correlate the
      response of mesenchymal-epithelial transition factor (MET) molecular status.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive cabozantinib-s-malate orally (PO) once daily (QD) on days 1-28.
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in
      the absence of disease progression or unacceptable toxicity. If temozolomide is not
      available, patients receive dacarbazine intravenously (IV) over 15-60 minutes on day 1.
      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
      At the time of progression patients may cross-over to Arm I.

      After completion of study treatment, patients are followed up every 12 weeks for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PFS4</measure>
    <time_frame>At 4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A patient will be declared a PFS4 success if they are on study and progression free for at least 4 months. This study will be declared promising if a one-sided chi-squared test for a difference in PFS4 rates yields a p-value of less than 0.10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Number of days from registration until disease progression (or death), assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The distribution of PFS time will be estimated using the method of Kaplan Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Number of days from registration until death, assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The distribution of OS time will be estimated using the method of Kaplan Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed response rate as determined by the RECIST criteria (version 1.1)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The confirmed response rates will be estimated by dividing the number of confirmed responders by the number of evaluable patients. 95% confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum grade for each type of adverse event, graded according to the NCI CTCAE version 4.0</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency tables will be created to look for patterns.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Ciliary Body and Choroid Melanoma, Medium/Large Size</condition>
  <condition>Ciliary Body and Choroid Melanoma, Small Size</condition>
  <condition>Iris Melanoma</condition>
  <condition>Metastatic Intraocular Melanoma</condition>
  <condition>Recurrent Intraocular Melanoma</condition>
  <condition>Stage IIIA Intraocular Melanoma</condition>
  <condition>Stage IIIB Intraocular Melanoma</condition>
  <condition>Stage IIIC Intraocular Melanoma</condition>
  <condition>Stage IV Intraocular Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm I (cabozantinib-s-malate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (temozolomide or dacarbazine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. At the time of progression patients may cross-over to Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabozantinib-s-malate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (cabozantinib-s-malate)</arm_group_label>
    <other_name>BMS-907351</other_name>
    <other_name>Cometriq</other_name>
    <other_name>XL184</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (temozolomide or dacarbazine)</arm_group_label>
    <other_name>SCH 52365</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (temozolomide or dacarbazine)</arm_group_label>
    <other_name>DIC</other_name>
    <other_name>DTIC</other_name>
    <other_name>DTIC-Dome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (cabozantinib-s-malate)</arm_group_label>
    <arm_group_label>Arm II (temozolomide or dacarbazine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed uveal melanoma that is metastatic or
             unresectable; if histologic or cytologic confirmation of the primary is not
             available, confirmation of the primary diagnosis of uveal melanoma by the treating
             investigator can be clinically obtained, as per standard practice for uveal melanoma;
             pathologic confirmation of diagnosis will be performed at the participating site

          -  Measurable disease defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded for non-nodal lesions and
             short axis for nodal lesions) as &gt;= 20 mm with conventional techniques or as &gt;= 10 mm
             with spiral computed tomography (CT) scan or magnetic resonance imaging (MRI)

          -  Prior therapies allowed, except for those treatments directed toward, or with
             activity against, c-Met or vascular endothelial growth factor/receptor (VEGF/R), and
             the chemotherapy agents temozolomide and dacarbazine; prior treatment must have been
             no earlier than 3 weeks prior to starting treatment with cabozantinib with exceptions
             noted and the following: at least 4 weeks since prior hepatic infusion or at least 2
             weeks since radiation therapy

          -  No cytotoxic chemotherapy including investigational cytotoxic chemotherapy or
             biologic agents (e.g., cytokines or antibodies) within the last 3 weeks, or
             nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment; at
             least 6 weeks must have elapsed if the last regimen included an anti-cytotoxic
             T-lymphocyte antigen 4 (CTLA4) antibody; patients must have experienced disease
             progression on their prior therapy in the opinion of the treating investigator

          -  No prior radiation therapy within the last 4 weeks, except as below

               -  To the thoracic cavity, abdomen, or pelvis within 12 weeks before the first dose
                  of study treatment, or has ongoing complications, or is without complete
                  recovery to &lt; grade 1 toxicity

               -  To bone or brain metastasis within 14 days before the first dose of study
                  treatment

               -  To any other site(s) within 28 days before the first dose of study treatment

               -  Prior radiation treatment may have included no more than 3000 centigray (cGy) to
                  fields including substantial bone marrow

          -  No prior radionuclide treatment within 6 weeks of the first dose of study treatment

          -  No prior treatment with a small molecule kinase inhibitor or a hormonal therapy
             within 14 days or 5 half-lives (whichever is longer)

          -  No concomitant anti-cancer therapy within 28 days of the first dose of study
             treatment, including other investigational agents; palliative radiation therapy will
             not be allowed while on protocol

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1 (Karnofsky &gt;= 70%)

          -  A corrected QT interval calculated by the Fridericia formula (QTcF) =&lt; 500 ms within
             28 days before randomization; note: if initial QTcF is found to be &gt; 500 ms, two
             additional electrocardiograms (EKGs) separated by at least 3 minutes should be
             performed; if the average of these three consecutive results for QTcF is =&lt; 500 ms,
             the patient meets eligibility in this regard

          -  Common Terminology Criteria for Adverse Events (CTCAE) recovered to baseline or CTCAE
             =&lt; grade 1 from toxicity due to all prior therapies except alopecia and other
             non-clinically significant adverse events (AEs)

          -  No active brain metastases or epidural disease; patients with brain metastases
             previously treated with whole brain radiation or radiosurgery or patients with
             epidural disease previously treated with radiation or surgery who are asymptomatic
             and do not require steroid treatment for at least 2 weeks before starting study
             treatment are eligible; neurosurgical resection of brain metastases or brain biopsy
             is permitted if completed at least 12 weeks before starting study treatment; baseline
             brain imaging with contrast-enhanced CT or MRI scans for patients with known brain
             metastases is required to confirm eligibility

          -  No clinically significant gastrointestinal bleeding within 24 weeks before the first
             dose of study treatment

          -  No hemoptysis of &gt;= 0.5 teaspoon (2.5 mL) of red blood within 12 weeks before the
             first dose of study treatment

          -  No signs indicative of pulmonary hemorrhage within 12 weeks before the first dose of
             study treatment

          -  No prior radiographic evidence of cavitating pulmonary lesion(s)

          -  No tumor in contact with, invading or encasing any major blood vessels

          -  No evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach,
             small or large bowel, rectum or anus), or any evidence of endotracheal or
             endobronchial tumor within 28 days before the first dose of treatment

          -  The patient may not have uncontrolled, significant intercurrent or recent illness
             including, but not limited to, the following conditions:

               -  Cardiovascular disorders including:

                    -  Congestive heart failure (CHF): New York Heart Association (NYHA) class III
                       (moderate) or class IV (severe) at the time of screening

                    -  Concurrent uncontrolled hypertension defined as sustained blood pressure
                       (BP) &gt; 140 mmHg systolic, or &gt; 90 mmHg diastolic despite optimal
                       antihypertensive treatment within 7 days of the first dose of study
                       treatment

                    -  Any history of congenital long QT syndrome

                    -  Any of the following within 24 weeks before the first dose of study
                       treatment:

                         -  Unstable angina pectoris

                         -  Clinically-significant cardiac arrhythmias

                         -  Stroke (including transient ischemic attack [TIA], or other ischemic
                            event)

                         -  Myocardial infarction

                         -  Thromboembolic event requiring therapeutic anticoagulation (Note:
                            patients with a venous filter [e.g. vena cava filter] are not eligible
                            for this study)

               -  Gastrointestinal disorders particularly those associated with a high risk of
                  perforation or fistula formation including:

                    -  Any of the following within 28 days before the first dose of study
                       treatment

                         -  Intra-abdominal tumor/metastases invading GI mucosa

                         -  Active peptic ulcer disease

                         -  Inflammatory bowel disease (including ulcerative colitis and Crohn's
                            disease), diverticulitis, cholecystitis, symptomatic cholangitis or
                            appendicitis

                         -  Malabsorption syndrome

                    -  Any of the following within 24 weeks before the first dose of study
                       treatment:

                         -  Abdominal fistula

                         -  Gastrointestinal perforation

                         -  Intra-abdominal abscess; Note: complete resolution of an
                            intra-abdominal abscess must be confirmed prior to initiating
                            treatment with cabozantinib even if the abscess occurred more that 24
                            weeks before the first dose of study treatment

                         -  Bowel obstruction or gastric outlet obstruction

               -  Other clinically significant disorders such as:

                    -  Serious non-healing wound/ulcer/bone fracture within 28 days before the
                       first dose of study treatment

                    -  History of organ transplant

                    -  Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7
                       days before the first dose of study treatment

                    -  History of major surgery as follows:

                         -  Major surgery in past 6 weeks of the first dose of cabozantinib if
                            there were no wound healing complications or within 24 weeks of the
                            first dose of cabozantinib if there were wound complications

                         -  Minor surgery within 4 weeks of the first dose of cabozantinib if
                            there were no wound healing complications or within 12 weeks of the
                            first dose of cabozantinib if there were wound complications

                         -  In addition, complete wound healing from prior surgery must be
                            confirmed at least 28 days before the first dose of cabozantinib
                            irrespective of the time from surgery

                    -  Active infection requiring systemic treatment within 28 days before the
                       first dose of study treatment as per the protocol template

          -  No concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin
             or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or
             antiplatelet agents (e.g., clopidogrel); low dose aspirin (=&lt; 81 mg/day), low-dose
             warfarin (=&lt; 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are
             permitted; please note that drugs that strongly induce or inhibit cytochrome P450 3A4
             (CYP3A4) or are associated with a risk of Torsades are not allowed; chronic
             concomitant treatment of CYP3A4 inducers is not allowed (e.g., dexamethasone,
             phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St.
             John's Wort); as part of the enrollment/informed consent procedures, the patient will
             be counseled on the risk of interactions with other agents, and what to do if new
             medications need to be prescribed or if the patient is considering a new
             over-the-counter medicine or herbal product; the following drugs are strong
             inhibitors of CYP3A4 and are not allowed during the treatment with cabozantinib:

               -  Boceprevir

               -  Indinavir

               -  Nelfinavir

               -  Lopinavir/ritonavir

               -  Saquinavir

               -  Telaprevir

               -  Ritonavir

               -  Clarithromycin

               -  Conivaptan

               -  Itraconazole

               -  Ketoconazole

               -  Mibefradil

               -  Nefazodone

               -  Posaconazole

               -  Voriconazole

               -  Telithromycin

               -  Drugs with possible or conditional risk of torsades should be used with caution
                  knowing that cabozantinib could prolong the QT interval

          -  Patients who are pregnant or nursing are not eligible; women of child bearing
             potential must have a negative serum or urine pregnancy test within 16 days prior to
             registration; women of child-bearing potential include:

               -  Any female who has experienced menarche and who has not undergone surgical
                  sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy)
                  or is not postmenopausal (defined as amenorrhea &gt;= 12 consecutive months)

               -  Women on hormone replacement therapy (HRT) with documented serum follicle
                  stimulating hormone (FSH) level &gt; 35m IU/mL

               -  Women who are using oral, implanted or injectable contraceptive hormones or
                  mechanical products such as an intrauterine device or barrier methods
                  (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence
                  or where partner is sterile (e.g., vasectomy)

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to cabozantinib, temozolomide and dacarbazine

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin =&lt; 1.5 × upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 5.0 × institutional upper limit of normal (for patients with metastases); AST
             (SGOT)/ALT (SGPT) =&lt; 2.5 × institutional upper limit of normal (for patients without
             metastases)

          -  Serum creatinine =&lt; 1.5 × ULN, OR calculated creatinine clearance &gt;= 30 mL/minute
             (modified Cockroft and Gault formula)

          -  Hemoglobin &gt;= 9 g/dL

          -  Serum albumin &gt;= 2.8 g/dL

          -  Urine protein/creatinine ratio (UPCR) =&lt; 1; if urine/protein creatinine (UPC) &gt;= 1,
             then a 24-hour urine protein must be assessed; eligible patients must have a 24-hour
             urine protein value &lt; 1 g

          -  Thyroid-stimulating hormone (TSH) within normal limits (WNL); supplementation is
             acceptable to achieve a TSH WNL

          -  No clinical or radiographic evidence of pancreatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Luke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NCI CTRP</last_name>
    <phone>866-319-4357</phone>
    <email>ncictro@mail.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Gynecologic Oncology LLC</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Hematology and Oncology PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hematology Consultants PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware Clinical and Laboratory Physicians PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beebe Health Campus</name>
      <address>
        <city>Rehoboth Beach</city>
        <state>Delaware</state>
        <zip>19971</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanticoke Memorial Hospital</name>
      <address>
        <city>Seaford</city>
        <state>Delaware</state>
        <zip>19973</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Wilmington Hospital</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S. Grubbs</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Stephen S. Grubbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Lutzky</last_name>
      <phone>305-674-2625</phone>
      <email>info@msccop.com</email>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jupiter Medical Center</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Lutzky</last_name>
      <phone>305-674-2625</phone>
      <email>info@msccop.com</email>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center CCOP</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Lutzky</last_name>
      <phone>305-674-2625</phone>
      <email>info@msccop.com</email>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kootenai Cancer Center</name>
      <address>
        <city>Post Falls</city>
        <state>Idaho</state>
        <zip>83854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason J. Luke</last_name>
      <phone>617-632-6588</phone>
      <email>jason_luke@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jason J. Luke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph I. Clark</last_name>
      <phone>708-226-4357</phone>
    </contact>
    <investigator>
      <last_name>Joseph I. Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Garneau, Stewart C MD (UIA Investigator)</name>
      <address>
        <city>Moline</city>
        <state>Illinois</state>
        <zip>61265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Spector</last_name>
      <phone>309-779-4200</phone>
    </contact>
    <investigator>
      <last_name>David M. Spector</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Porubcin, Michael MD (UIA Investigator)</name>
      <address>
        <city>Moline</city>
        <state>Illinois</state>
        <zip>61265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Spector</last_name>
      <phone>309-779-4200</phone>
    </contact>
    <investigator>
      <last_name>David M. Spector</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spector, David MD (UIA Investigator)</name>
      <address>
        <city>Moline</city>
        <state>Illinois</state>
        <zip>61265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Spector</last_name>
      <phone>309-779-4200</phone>
    </contact>
    <investigator>
      <last_name>David M. Spector</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trinity Medical Center</name>
      <address>
        <city>Moline</city>
        <state>Illinois</state>
        <zip>61265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Spector</last_name>
      <phone>309-779-4200</phone>
    </contact>
    <investigator>
      <last_name>David M. Spector</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Regional Health Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>Illinois</state>
        <zip>62864</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Greeley Medical Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-William R Bliss Cancer Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Constantinou, Costas L MD (UIA Investigator)</name>
      <address>
        <city>Bettendorf</city>
        <state>Iowa</state>
        <zip>52722</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Spector</last_name>
      <phone>309-779-4200</phone>
    </contact>
    <investigator>
      <last_name>David M. Spector</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Boone</name>
      <address>
        <city>Boone</city>
        <state>Iowa</state>
        <zip>50036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed M. Milhem</last_name>
      <phone>800-237-1225</phone>
    </contact>
    <investigator>
      <last_name>Mohammed M. Milhem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Jefferson</name>
      <address>
        <city>Jefferson</city>
        <state>Iowa</state>
        <zip>50129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Marshalltown</name>
      <address>
        <city>Marshalltown</city>
        <state>Iowa</state>
        <zip>50158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J. Merchant</last_name>
      <phone>515-239-2621</phone>
    </contact>
    <investigator>
      <last_name>Joseph J. Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center-Sioux City</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald B. Wender</last_name>
      <phone>712-252-0088</phone>
    </contact>
    <investigator>
      <last_name>Donald B. Wender</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Regional Medical Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald B. Wender</last_name>
      <phone>712-252-0088</phone>
    </contact>
    <investigator>
      <last_name>Donald B. Wender</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology Oncology Associates</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald B. Wender</last_name>
      <phone>712-252-0088</phone>
    </contact>
    <investigator>
      <last_name>Donald B. Wender</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's South Hospital</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City CCOP</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason J. Luke</last_name>
      <phone>866-790-4500</phone>
    </contact>
    <investigator>
      <last_name>Jason J. Luke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason J. Luke</last_name>
      <phone>866-790-4500</phone>
    </contact>
    <investigator>
      <last_name>Jason J. Luke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason J. Luke</last_name>
      <phone>866-790-4500</phone>
    </contact>
    <investigator>
      <last_name>Jason J. Luke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Battle Creek</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology - Escanaba</name>
      <address>
        <city>Escanaba</city>
        <state>Michigan</state>
        <zip>49431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Rapids Clinical Oncology Program</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health Saint Mary's</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology - Iron Mountain</name>
      <address>
        <city>Iron Mountain</city>
        <state>Michigan</state>
        <zip>49801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health Mercy Campus</name>
      <address>
        <city>Muskegon</city>
        <state>Michigan</state>
        <zip>49444</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Reed City Hospital</name>
      <address>
        <city>Reed City</city>
        <state>Michigan</state>
        <zip>49677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Munson Medical Center</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miller-Dwan Hospital</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Saint Mary's Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Duluth Clinic CCOP</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert R. McWilliams</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Robert R. McWilliams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth Cancer Center</name>
      <address>
        <city>Branson</city>
        <state>Missouri</state>
        <zip>65616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centerpoint Medical Center LLC</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <zip>64057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital-Joplin</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Hematology and Oncology Associates Incorporated</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's East - Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liberty Hospital</name>
      <address>
        <city>Liberty</city>
        <state>Missouri</state>
        <zip>64068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Clinic-Rolla-Cancer and Hematology</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Regional Medical Center</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Oncology Inc</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Louis Cancer and Breast Institute-South City</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107-7000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Healthcare</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Consortium CCOP</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bozeman Deaconess Hospital</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint James Community Hospital and Cancer Treatment Center</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benefis Healthcare- Sletten Cancer Institute</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Peter's Community Hospital</name>
      <address>
        <city>Helena</city>
        <state>Montana</state>
        <zip>59601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalispell Regional Medical Center</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Patrick Hospital - Community Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Ellerton</last_name>
      <phone>702-384-0013</phone>
    </contact>
    <investigator>
      <last_name>John A. Ellerton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Ellerton</last_name>
      <phone>702-384-0013</phone>
    </contact>
    <investigator>
      <last_name>John A. Ellerton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Crawford</last_name>
      <phone>888-275-3853</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Crawford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists PA</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter R. Watson</last_name>
      <phone>252-559-2200</phone>
    </contact>
    <investigator>
      <last_name>Peter R. Watson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul D. Savage</last_name>
      <phone>336-713-6771</phone>
    </contact>
    <investigator>
      <last_name>Paul D. Savage</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clackamas Radiation Oncology Center</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>97015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Milwaukie Hospital</name>
      <address>
        <city>Milwaukie</city>
        <state>Oregon</state>
        <zip>97222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Newberg Medical Center</name>
      <address>
        <city>Newberg</city>
        <state>Oregon</state>
        <zip>97132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Willamette Falls Medical Center</name>
      <address>
        <city>Oregon City</city>
        <state>Oregon</state>
        <zip>97045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Saint Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Oncology Research Consortium</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Easley</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Andrews</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Butternut</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute/Greenville CCOP</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Seneca</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compass Oncology Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Southwest Medical Center</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology Limited at Saint Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology at Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301-3526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Family Memorial Hospital</name>
      <address>
        <city>Manitowoc</city>
        <state>Wisconsin</state>
        <zip>54221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Area Medical Center</name>
      <address>
        <city>Marinette</city>
        <state>Wisconsin</state>
        <zip>54143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy K. Harker-Murray</last_name>
      <phone>414-805-4380</phone>
    </contact>
    <investigator>
      <last_name>Amy K. Harker-Murray</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology - Oconto Falls</name>
      <address>
        <city>Oconto Falls</city>
        <state>Wisconsin</state>
        <zip>54154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Nicholas Hospital</name>
      <address>
        <city>Sheboygan</city>
        <state>Wisconsin</state>
        <zip>53081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology - Sturgeon Bay</name>
      <address>
        <city>Sturgeon Bay</city>
        <state>Wisconsin</state>
        <zip>54235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>800-432-6049</phone>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Oncology</name>
      <address>
        <city>Casper</city>
        <state>Wyoming</state>
        <zip>82609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Welch Cancer Center</name>
      <address>
        <city>Sheridan</city>
        <state>Wyoming</state>
        <zip>82801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>April 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
